Latrophilin‐3 as a downstream effector of the androgen receptor induces urothelial tumorigenesis
Molecular Carcinogenesis · 2024
DOI: 10.1002/mc.23783 ↗At a glance
Journal article in Molecular Carcinogenesis, 2024. Written by Takuro Goto and 5 co-authors. Institution: Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA. Major MEDLINE topics: Receptors, Androgen, Urinary Bladder Neoplasms, Urothelium, Receptors, Peptide. Cited 6 times so far (Crossref); 29 references. Funded by: Ferring Research Institute.
Abstract (original language)
Emerging evidence indicates that androgen receptor (AR) signaling plays a critical role in the pathogenesis of male‐dominant urothelial cancer. Meanwhile, latrophilins (LPHNs), a group of the G‐protein‐coupled receptor to which a spider venom latrotoxin is known to bind, remain largely uncharacterized in neoplastic diseases. The present study aimed to determine the functional role of LPHN3 (encoded by the ADGRL3 gene), in association with AR signaling, in urothelial tumorigenesis. In human normal urothelial SVHUC cells, AR overexpression and androgen treatment considerably increased the expression levels of ADGRL3 /LPHN3, while chromatin immunoprecipitation assay revealed the binding of AR to the promoter region of ADGRL3 . In SVHUC or SVHUC‐AR cells with exposure to a chemical carcinogen 3‐methylcholanthrene, LPHN3 activation via ligand (e.g., α‐latrotoxin, FLRT3) treatment during the process of the neoplastic/malignant transformation or LPHN3 knockdown via shRNA virus infection induced or reduced, respectively, the oncogenic activity. In N ‐butyl‐ N ‐(4‐hydroxybutyl)nitrosamine‐treated female mice, α‐latrotoxin or FLRT3 injection accelerated the development of bladder tumors. Immunohistochemistry in surgical specimens further showed the significantly elevated expression of LPHN3 in non‐muscle‐invasive bladder tumors, compared with adjacent normal urothelial tissues, which was associated with a marginally ( p = 0.051) higher risk of disease recurrence after transurethral resection. In addition, positivity of LPHN3 and AR in these tumors was strongly correlated. These findings indicate that LPHN3 functions as a downstream effector of AR and promotes urothelial tumorigenesis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA.
- James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.
- Department of Urology, University of Rochester Medical Center, Rochester, New York, USA.
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID profiles: Hiroshi Miyamoto
Funding
- Ferring Research Institute
Cite
APA
Goto, T., Yasui, M., Teramoto, Y., Nagata, Y., Mizushima, T., & Miyamoto, H. (2024). Latrophilin‐3 as a downstream effector of the androgen receptor induces urothelial tumorigenesis. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23783
Vancouver
Goto T, Yasui M, Teramoto Y, Nagata Y, Mizushima T, Miyamoto H. Latrophilin‐3 as a downstream effector of the androgen receptor induces urothelial tumorigenesis. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23783
BibTeX
@article{Goto2024,
author = {Goto, Takuro and Yasui, Masato and Teramoto, Yuki and Nagata, Yujiro and Mizushima, Taichi and Miyamoto, Hiroshi},
title = {Latrophilin‐3 as a downstream effector of the androgen receptor induces urothelial tumorigenesis},
journal = {Molecular Carcinogenesis},
year = {2024},
doi = {10.1002/mc.23783}
}
EUVIMED